文献速递肾血管病与高血压

难治性高血压的评估与管理:2024核心课程

Evaluation and Management of Resistant Hypertension: Core Curriculum 2024.
PubMed 文献 · Am J Kidney Dis · 2024-07-20

难治性高血压定义为尽管确认坚持使用3种一线降压药仍血压高于目标值,或使用4种及以上最大或最大耐受剂量药物血压才达标。识别真性难治性高血压需准确诊室血压测量并通过诊室外血压测量排除白大衣效应。患者心血管事件风险更高且更可能合并可治疗的继发性病因,治疗包括持续生活方式干预、优化一线长效药物并逐步添加二至四线药物、系统评估继发性病因及多学科团队协作,新药和器械治疗已获批但最佳作用仍在研究中。

要点

  • 难治性高血压需准确诊室血压和诊室外血压排除白大衣效应。
  • 优先优化一线每日一次长效药物,耐受后逐步添加二至四线药物。
  • 系统评估并处理继发性病因,采用多学科团队协作管理。

核心结论

  • 难治性高血压患者心血管事件风险更高,需准确血压测量排除白大衣效应并系统评估继发性病因。
  • 有效治疗包括生活方式干预、促进用药依从性、优化一线长效药物并逐步添加后续药物及多学科协作。

研究设计与样本

  • 本文为Am J Kidney Dis发表的2024核心课程综述,总结难治性高血压的评估与管理。

主要发现

  • 难治性高血压定义为确认坚持3种一线降压药仍血压高于目标值,或使用4种及以上最大或最大耐受剂量药物血压才达标。
  • 患者更可能合并可治疗的继发性病因,新药和器械治疗已获批但最佳作用仍在研究中。

关键数值与推荐

  • 难治性高血压定义:确认坚持3种一线降压药仍血压高于目标值,或使用4种及以上最大或最大耐受剂量药物血压才达标。
  • 药理学治疗应优先优化一线每日一次长效药物,耐受后逐步添加二线、三线和四线药物。

临床怎么用

  • 准确诊室血压测量并通过诊室外血压测量排除白大衣效应以识别真性难治性高血压。
  • 持续生活方式干预并与患者协作检测和解决最佳用药依从性的障碍。
  • 优化一线每日一次长效药物后逐步添加二至四线药物,系统评估并处理继发性病因。
  • 采用包括有难治性高血压治疗经验临床医生的多学科团队协作方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Resistant hypertension is defined as blood pressure above goal despite confirmed adherence to 3 first-line antihypertensive agents or when blood pressure is controlled with 4 or more medications at maximal or maximally tolerated doses. In addition to meeting these criteria, identifying patients with true resistant hypertension requires both accurate in-office blood pressure measurement as well as excluding white coat effects through out-of-office blood pressure measurements. Patients with resistant hypertension are at higher risk for adverse cardiovascular events and are more likely to have a potentially treatable secondary cause contributing to their hypertension. Effective treatment of resistant hypertension includes ongoing lifestyle modifications and collaboration with patients to detect and address barriers to optimal medication adherence. Pharmacologic treatment should prioritize optimizing first-line, once daily, longer acting medications followed by the stepwise addition of second-, third-, and fourth-line agents as tolerated. Physicians should systematically evaluate for and address any underlying secondary causes. A coordinated, multidisciplinary team approach including clinicians with experience in treating resistant hypertension is essential. New treatment options, including both pharmacologic and device-based therapies, have recently been approved, and more are in the pipeline; their optimal role in the management of resistant hypertension is an area of ongoing research.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Cluett JL, William JH. Evaluation and Management of Resistant Hypertension: Core Curriculum 2024. Am J Kidney Dis. 2024. PMID: 39033452. doi:10.1053/j.ajkd.2024.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。